Skip to content
Home/Companies/Biotech/EOS

EOS

Biotech·Italy·Exited 2013·Held 1yr
Entry
2012
Hold
1yr
Exit
2013

Who owns EOS?

EOS is an Italian Biotech company, now owned by Clovis Oncology, which acquired it in 2013 from Sofinnova Partners.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Capital VII · 2012 · Life Sciences VC

Key facts

HQItaly
SectorBiotech
Exit Type
Trade Sale
Buyer
Clovis Oncology
Exit Year
2013

More from Sofinnova Capital VII

Other portfolio companies in the same fund.

Pixium Vision
Exited 2024
MedTechFrance· 2013
to Science Corporation
Advanced Perfusion Diagnostics
Exited 2019
MedTechFrance· 2012
to Vygon
Ascendis Pharma
Exited 2015
BiotechDenmark· 2012
GlycoVaxyn
Exited 2015
BiotechSwitzerland· 2012
to GSK

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns EOS?

EOS is now owned by Clovis Oncology, which acquired it in 2013 from Sofinnova Partners.

When did Clovis Oncology acquire EOS?

Clovis Oncology acquired EOS in 2013, buying from Sofinnova Partners.

Who did EOS sell to?

Sofinnova Partners sold EOS to Clovis Oncology in 2013 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue